Related Experiment Video
Updated: Aug 30, 2026

One-step Metabolomics: Carbohydrates, Organic and Amino Acids Quantified in a Single Procedure
Published on: June 25, 2010
Long-term outcome of patients with urea cycle disorders and the question of neonatal screening
1Laboratoire Central de Chimie Clinique, Centre Hospitalier Universitaire Vaudois, Bugnon 46, 1011, Lausanne, Switzerland. Claude.Bachmann@chuv.hospvd.ch
Insights
Neonatal screening for urea cycle disorders shows improved survival with newer therapies, but long-term outcomes and neurodevelopmental impact remain similar to older treatments. Early detection is crucial, but its benefits versus parental acceptance are debated.
Area of Science:
- Biochemistry
- Genetics
- Pediatrics
Background:
- Urea cycle disorders (UCDs) are genetic conditions affecting ammonia metabolism.
- Neonatal screening principles raise questions about effective treatments for UCDs.
- Current treatments aim to manage hyperammonemia and improve patient outcomes.
Purpose of the Study:
- To compare the long-term survival and neurodevelopmental outcomes of patients with UCDs treated with different therapeutic approaches.
- To evaluate the effectiveness of neonatal screening for UCDs in preventing irreversible damage.
Main Methods:
- Retrospective study of 88 patients with UCDs.
- Comparison of outcomes between protein restriction alone versus therapy with citrulline/arginine and benzoate.
- Data collected via questionnaires.
Main Results:
- Newer therapies improved survival in neonatally presenting UCD patients, but with increased rates of neurodevelopmental delay.
- Long-term outcomes did not significantly differ between the treatment groups.
- A significant percentage of patients (56-67%) showed symptoms within the first week of life.
Conclusions:
- Neonatal screening for UCDs may not prevent irreversible damage due to early symptom onset.
- Early diagnosis and prompt ammonia level determination are critical, especially in sick neonates.
- Establishing specialized metabolic centers is essential for effective screening, diagnosis, and long-term patient management.
Unlabelled:
With regard to the principles established for neonatal population screening, the question arises whether for patients with urea cycle disorders there is an accepted treatment which really affects the disease course and prognosis as compared to the natural history of these diseases. A retrospective study of 88 patients was performed. Based on questionnaires, the survival rate and neurodevelopmental outcome of patients treated with protein restriction alone was compared to the new therapy introduced in the 1980s with added citrulline/arginine, essential amino acids for improving the amino acid composition of the restricted natural protein and benzoate. Survival of patients with neonatal presentation was improved by the extensive therapy but this mostly at the cost of an increasing number of retarded patients. Long-term outcome did not differ significantly between the two treatments. Of all patients, 56% were symptomatic within 4 days of age and 67% within the 1st week. Thus a prevention of irreversible damage by neonatal screening on blood obtained at 3-4 days of life is questionable. Whether the benefit of obtaining a rapid diagnosis, e.g. for allowing proper counselling and prospective treatment, is acceptable for the parents of prospective patients remains open. The organisation of a dense network of specialised metabolic centres with sufficient staff and resources is a prior condition for any screening programme in order to ensure the rapid diagnosis, follow-up of treatment and counselling of a cumulative number of affected chronic patients needing this support. A commitment on a long-term basis by the institutions is needed in view of the health budget restrictions.
Conclusion:
in the short term, the goal is to detect hyperammonaemic patients as early as possible with special emphasis on sick neonates. In practice, quantitative plasma ammonia determination without delay is recommended in any newborn for whom a sepsis work-up is considered and in children who refuse feeding or vomit and show alterations of consciousness and/or neurological symptoms.
Related Concept Videos
Urea Cycle
Inborn Errors of Metabolism
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Serum Laboratory Studies, Stool Test, Breath Test
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

